XOMA Royalty (NASDAQ:XOMA – Get Free Report) and BioHarvest Sciences (NASDAQ:BHST – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.
Institutional & Insider Ownership
95.9% of XOMA Royalty shares are held by institutional investors. 7.2% of XOMA Royalty shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings and Valuation
This table compares XOMA Royalty and BioHarvest Sciences”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| XOMA Royalty | $11.66 million | 29.84 | $31.71 million | $1.46 | 20.01 |
| BioHarvest Sciences | $25.19 million | 2.82 | -$12.91 million | ($0.68) | -6.37 |
XOMA Royalty has higher earnings, but lower revenue than BioHarvest Sciences. BioHarvest Sciences is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent recommendations for XOMA Royalty and BioHarvest Sciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| XOMA Royalty | 1 | 2 | 3 | 0 | 2.33 |
| BioHarvest Sciences | 1 | 0 | 3 | 0 | 2.50 |
XOMA Royalty presently has a consensus price target of $61.60, suggesting a potential upside of 110.81%. BioHarvest Sciences has a consensus price target of $13.00, suggesting a potential upside of 200.23%. Given BioHarvest Sciences’ stronger consensus rating and higher probable upside, analysts clearly believe BioHarvest Sciences is more favorable than XOMA Royalty.
Profitability
This table compares XOMA Royalty and BioHarvest Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| XOMA Royalty | 45.75% | 10.32% | 3.49% |
| BioHarvest Sciences | -36.33% | -1,041.86% | -36.06% |
Volatility and Risk
XOMA Royalty has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, BioHarvest Sciences has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500.
Summary
XOMA Royalty beats BioHarvest Sciences on 9 of the 13 factors compared between the two stocks.
About XOMA Royalty
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
About BioHarvest Sciences
BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.
Receive News & Ratings for XOMA Royalty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Royalty and related companies with MarketBeat.com's FREE daily email newsletter.
